TY - JOUR T1 - Photodynamic therapy with verteporfin for anterior segment neovascularizations in neovascular glaucoma. AU - Parodi,Maurizio Battaglia, AU - Iacono,Pierluigi, PY - 2003/10/21/received PY - 2004/02/09/accepted PY - 2004/7/6/pubmed PY - 2004/9/1/medline PY - 2004/7/6/entrez SP - 157 EP - 8 JF - American journal of ophthalmology JO - Am J Ophthalmol VL - 138 IS - 1 N2 - PURPOSE: To evaluate photodynamic therapy (PDT) with verteporfin for iris and angle neovascularization in eyes with neovascular glaucoma. DESIGN: Interventional case series. METHODS: A prospective, noncomparative case series included four patients (four eyes) with neovascular glaucoma. PDT was performed following the parameters of treatment of age-related macular degeneration with photodynamic therapy Study Group (TAP). The laser was directed at the anterior chamber angle and iris surface using a Goldmann three-mirror contact lens. Iris and angle neovascularization were quantified using the number of clock hours involved. Outcome measures were obliteration of neovascularization and decrease of intraocular pressure (IOP). RESULTS: One week after PDT, we registered complete obliteration of angle neovascularization and partial occlusion of iris neovascularization. Subsequent reopening of angle neovascularization was detectable at 1 month. Intraocular pressure diminished considerably after 1 week, with a subsequent tendency toward stabilization. CONCLUSIONS: Photodynamic therapy can be used safely and effectively in the early phases of neovascular glaucoma to achieve angle neovascularization obliteration and IOP reduction. SN - 0002-9394 UR - https://www.unboundmedicine.com/medline/citation/15234305/Photodynamic_therapy_with_verteporfin_for_anterior_segment_neovascularizations_in_neovascular_glaucoma_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0002939404001412 DB - PRIME DP - Unbound Medicine ER -